We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
Novo Nordisk | NYSE:NVO | NYSE | Common Stock |
Price Change | % Change | Share Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|
-1.67 | -1.32% | 125.21 | 7,506 | 11:06:12 |
U.S. Securities and Exchange Commission
100 F Street, N.E.
Washington, D.C. 20549
February 9, 2017
Re: Notice of disclosure filed in Exchange Act Annual Report under Section 219 of the Iran Threat Reduction and Syria Human Rights Act of 2012 and Section 13(r) of the Exchange Act
Dear Sirs,
Pursuant to Section 219 of the Iran Threat Reduction and Syria Human Rights Act of 2012 and Section 13(r) of the Securities Exchange Act of 1934, as amended, notice is hereby provided that Novo Nordisk A/S has made disclosure pursuant to those provisions in its Annual Report on Form 20-F for the year ended December 31, 2016, which was filed with the Securities and Exchange Commission on February 9, 2017.
Sincerely,
/s/ Lars Fruergaard Jørgensen | /s/ Jesper Brandgaard | ||
Lars Fruergaard Jørgensen | Jesper Brandgaard | ||
President and Chief Executive Officer | Executive Vice President and | ||
Chief Financial Officer |
Novo Nordisk A/S | Novo Allé | Telephone: | Internet: |
DK-2880 Bagsværd | +45 4444 8888 | novonordisk.com | |
Denmark | |||
Telefax: | CVR Number: | ||
+45 4444 6626 | 24256790 |
1 Year Novo Nordisk Chart |
1 Month Novo Nordisk Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions